Shawn J Stachel

This inventor holds 37 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 24 EPO patents, primarily in Alzheimer's Disease Treatment. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Merck Sharp & Dohme LLC. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shawn J Stachel. Retrieved from https://idiyas.com/inventor/shawn-j-stachel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 4)

% Patents Active = 89.2

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 24 (Patent Applications = 19)

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 141(Granted Patents)

Location History:

Perkasie, NJ (US) (2005)
Perkasie, PA (US) (2006 - 2023)

Company Filing History:

27 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

patents

4. 2 out of 519

Sloan-Kettering Institute for Cancer Research

patents

5. 1 out of 47

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

patents

6. 1 out of 63

Sunesis Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Beta-Secretase Inhibitors

NAV1.8 Inhibitors

PDE2 Inhibitors

CGRP Receptor Antagonists

Liver X Receptor Agonists

TrkA Kinase Inhibitors

Cathepsin Cysteine Protease Inhibitors

Spiropyrrolidine

Pyrrolidine Derivatives

Aminoimidazole Compounds

Phenylcarboxamide Compounds

Macrocyclic Compounds

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679807 - Modified isoindolinones as glucosylceramide synthase inhibitors (2026-07-14),

2. 12516046 - 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors (2026-01-06),

3. 12344595 - 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors (2025-07-01),

4. 12331018 - Pyrrolidine orexin receptor agonists (2025-06-17),

5. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors (2025-01-14),

6. 11655216 - Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use (2023-05-23),

7. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors (2022-07-05),

8. 10961215 - N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-03-30),

9. 10894775 - Piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-01-19),

10. 10287293 - Bicyclic heterocyclic compounds as PDE2 inhibitors (2019-05-14),

11. 10239849 - Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use (2019-03-26),

12. 10174037 - Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors (2019-01-08),

13. 10160762 - 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors (2018-12-25),

14. 9656990 - Cathepsin cysteine protease inhibitors (2017-05-23),

15. 9573913 - Cathepsin cysteine protease inhibitors (2017-02-21),

As an assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with an article about inventor Shawn J Stachel.

Title: Shawn J Stachel: Pioneering Inventor in Pharmaceutical Innovations

Introduction:

Shawn J Stachel is a highly accomplished inventor based in Perkasie, PA, US, with a remarkable portfolio of 32 patents. His pioneering work in the field of pharmaceutical innovations has significantly contributed to advancements in medicine.

Latest Patents:

Shawn J Stachel's latest patents showcase his expertise in drug discovery and development. One of his recent patents, titled "Aryl and heteroaryl ether derivatives as liver X receptor beta agonists," focuses on compounds that act as Liver X receptor (LXRβ) agonists, with potential applications in treating inflammatory diseases and disorders like Alzheimer's disease. Another notable patent, "2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors," highlights his work on Na1.8 channel inhibitors for pain management and other related conditions.

Career Highlights:

Having worked at companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc., Shawn J Stachel has honed his skills in pharmaceutical research and development. His innovative approach to drug discovery has led to several breakthroughs in the field, earning him recognition as a leading inventor in the industry.

Collaborations:

Throughout his career, Shawn J Stachel has collaborated with esteemed professionals in the field, including coworkers Craig Alan Coburn and Joseph P Vacca. These collaborations have fostered a spirit of innovation and cooperation, leading to the successful development of groundbreaking pharmaceutical solutions.

Conclusion:

In conclusion, Shawn J Stachel's dedication to innovation and his invaluable contributions to the field of pharmaceutical inventions have cemented his legacy as a pioneering inventor. His work continues to inspire and drive advancements in medicine, offering hope for patients suffering from a range of disorders.

Profile summary based on public USPTO records.